-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ulcerative colitis (UC) is increasingly recognized as a progressive disease, and patients with a long course of disease may develop colorectal stenosis
Ulcerative colitis (UC) is increasingly recognized as a progressive disease, patients with a long course may develop colorectal stenosis Ulcerative colitis (UC) is increasingly recognized as a progressive disease with a long course Of patients may develop colorectal stenosis andulcerative colitis
This is a multicenter retrospective cohort study to evaluate the incidence of colorectal stenosis and related risk factors in a large-scale UC patient population
Survival rate
Survival rateIn total, 439 UC patients were included
The incidence of colorectal stenosis was 3.
Montreal Class A3 (age>40 years; p=0.
Montreal A3 grade and UC patients with a history of steroid exposure have a higher risk of colorectal stenosis than ordinary patients, and the use of mesalazine can reduce the risk Montreal A3 grade and UC patients with a history of steroid exposure have a higher risk of colorectal stenosis For ordinary patients, the use of mesalazine can reduce the risk and prevent
Original source:
Original source:Pierre-Antoine Laurain, et al.
Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study
in this message